Key Takeaways
- • Sheridan Capital Partners raised nearly $1.35 billion across two new flagship funds, according to the WSJ report dated October 7, 2026.
- • Fund III closed at its hard cap of $575 million, significantly oversubscribed despite a challenging fundraising environment and exceeding its $450 million target.
- • Fund II previously closed at $306 million, focused on lower middle-market buyouts and growth equity investments in healthcare across the U.S. and Canada.
- • The Chicago-based healthcare private equity firm is targeting $1.1 billion for its fourth flagship fund, indicating continued momentum in capital deployment.
- • Sheridan demonstrated strong operational execution in 2025, completing three platform acquisitions, nine add-ons, and realizing two successful exits including sales to Coalesce Capital and Carlyle.
Summary
Sheridan Capital Partners, a Chicago-based healthcare-focused private equity firm, has successfully closed two flagship funds totaling nearly $1.35 billion, as reported by the Wall Street Journal on October 7, 2026. The dual closings underscore sustained investor confidence in the firm's lower middle-market investment thesis despite macroeconomic headwinds affecting the broader fundraising environment.
Fund III achieved its hard cap at $575 million after becoming significantly oversubscribed, exceeding the firm's original $450 million target. The oversubscription signals strong institutional demand for Sheridan's healthcare-focused strategy and track record. Fund II previously closed at $306 million. Both funds are positioned to make investments in lower middle-market companies across healthcare verticals in the U.S. and Canadian markets, consistent with Sheridan's established investment focus.
The fundraising success follows a productive 2025 for the firm. Sheridan completed three platform acquisitions during the year, executed nine add-on investments, and realized two exits: DAS Health (sold to Coalesce Capital, with Sheridan retaining a minority stake) and Tarrytown pharmacy (acquired by Carlyle Group, with Sheridan maintaining minority ownership). These realizations demonstrated the firm's ability to execute value creation across its healthcare thesis. The firm also expanded its team by welcoming four senior-level hires to strengthen operational and investment capabilities.
Looking forward, Sheridan Capital Partners is targeting $1.1 billion for its fourth flagship fund, indicating the firm's intention to sustain its fundraising momentum and expand its deployment capacity in the healthcare lower middle market.
Fund III achieved its hard cap at $575 million after becoming significantly oversubscribed, exceeding the firm's original $450 million target. The oversubscription signals strong institutional demand for Sheridan's healthcare-focused strategy and track record. Fund II previously closed at $306 million. Both funds are positioned to make investments in lower middle-market companies across healthcare verticals in the U.S. and Canadian markets, consistent with Sheridan's established investment focus.
The fundraising success follows a productive 2025 for the firm. Sheridan completed three platform acquisitions during the year, executed nine add-on investments, and realized two exits: DAS Health (sold to Coalesce Capital, with Sheridan retaining a minority stake) and Tarrytown pharmacy (acquired by Carlyle Group, with Sheridan maintaining minority ownership). These realizations demonstrated the firm's ability to execute value creation across its healthcare thesis. The firm also expanded its team by welcoming four senior-level hires to strengthen operational and investment capabilities.
Looking forward, Sheridan Capital Partners is targeting $1.1 billion for its fourth flagship fund, indicating the firm's intention to sustain its fundraising momentum and expand its deployment capacity in the healthcare lower middle market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.